Vir Biotechnology (VIR) EBIT (2018 - 2025)
Historic EBIT for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$173.4 million.
- Vir Biotechnology's EBIT rose 2501.51% to -$173.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$548.6 million, marking a year-over-year increase of 992.95%. This contributed to the annual value of -$587.2 million for FY2024, which is 1419.54% up from last year.
- According to the latest figures from Q3 2025, Vir Biotechnology's EBIT is -$173.4 million, which was up 2501.51% from -$118.4 million recorded in Q2 2025.
- In the past 5 years, Vir Biotechnology's EBIT ranged from a high of $1.0 billion in Q1 2022 and a low of -$231.3 million during Q3 2024
- For the 5-year period, Vir Biotechnology's EBIT averaged around -$23.6 million, with its median value being -$139.5 million (2025).
- Over the last 5 years, Vir Biotechnology's EBIT had its largest YoY gain of 73910.28% in 2022, and its largest YoY loss of 46911.35% in 2022.
- Vir Biotechnology's EBIT (Quarter) stood at $571.8 million in 2021, then crashed by 126.32% to -$150.5 million in 2022, then increased by 7.63% to -$139.0 million in 2023, then grew by 15.73% to -$117.2 million in 2024, then tumbled by 48.05% to -$173.4 million in 2025.
- Its EBIT stands at -$173.4 million for Q3 2025, versus -$118.4 million for Q2 2025 and -$139.5 million for Q1 2025.